We are live on ! Find out more
KYNB

Kyntra Bio

7.95 USD
-0.15
1.85%
At close Updated Aug 26, 10:04 AM EDT
1 day
-1.85%
5 days
12.13%
1 month
12.77%
3 months
16.06%
6 months
14.06%
Year to date
-13.21%
1 year
-23.19%
5 years
-97.22%
10 years
-98.23%
 

About: Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Employees: 34

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 20%
Neutral 60%
Negative 20%
Neutral
Seeking Alpha
12 days ago
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Negative
Zacks Investment Research
12 days ago
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
Kyntra Bio (KYNB) came out with a quarterly loss of $4.68 per share versus the Zacks Consensus Estimate of a loss of $3.18. This compares to a loss of $3.38 per share a year ago.
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
12 days ago
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company's recent developments.
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Positive
Zacks Investment Research
22 days ago
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Neutral
GlobeNewsWire
2 months ago
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) treated with roxadustat will be presented as a poster at the European Hematology Association (EHA) Congress 2026, taking place June 11-14, 2026 in Stockholm, Sweden.
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
Neutral
Seeking Alpha
3 months ago
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Kyntra Bio (KYNB) came out with a quarterly loss of $3.74 per share versus the Zacks Consensus Estimate of a loss of $3.36. This compares to a loss of $4 per share a year ago.
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
3 months ago
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the first quarter 2026 and provided an update on the company's recent developments.
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
3 months ago
Kyntra Bio to Report First Quarter 2026 Financial Results
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Kyntra Bio to Report First Quarter 2026 Financial Results
Positive
Zacks Investment Research
4 months ago
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
Price charts implemented using Lightweight Charts™